Ulcerative Colitis: Tofacitinib's Impact on Blood Clotting

We are studying how tofacitinib affects blood clotting and platelet function in patients with ulcerative colitis. This trial also compares its effects to other treatments and collects samples for future research.

3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesOralInjectionGastroenterologyHematology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Adalimumab
Adalimumab is a biologic that blocks a key inflammatory protein (TNF) to reduce inflammation in autoimmune conditions like rheumatoid arthritis and Crohn's disease.
Golimumab
Golimumab is a substance that reduces inflammation by blocking a protein, TNF, used to treat autoimmune conditions like rheumatoid arthritis and ulcerative colitis.
Infliximab
Infliximab is a substance that reduces inflammation by blocking a protein called TNF and is used for autoimmune conditions like rheumatoid arthritis and Crohn's.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Universitario De La Princesa
Digestivo
Ciudad Lineal, Spain
Sponsor: Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.